SickKids is providing the C-GUIDE™ tool evaluation of iHope's genomic testing for the diagnosis, care, and well-being ...

Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...

Bausch Health Companies Inc. (NYSE:BHC) is one of the most undervalued Canadian stocks to buy according to hedge funds. On January 23, Bausch Health announced the results of its global Phase 3 RED-C ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support ...

March 23-25, 2026 | San Diego, CA The 11th Innate Killer Summit returns, bringing together global leaders advancing natural killer (NK) cell–based immunotherapies. The meeting continues as the longest ...

Novel KIF18A inhibitor, ATX-295, shows enriched activity in ovarian and TNBC preclinical models with whole genome doubling First-in-class DHX9 inhibitor, ATX-559, demonstrates potent activity in ...

Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing ...

The study was unlikely to meet its primary endpoint based on overall efficacy and safety results from a pre-planned futility analysis. BeiGene has made the decision to end the clinical development ...

Roswell, Georgia, United States, 30th Jan 2026 - North Atlanta Behavioral Health announces its services of clinically ...

This course offered by Stack Education is designed to teach the fundamentals of clinical trials research. It is a six-week online course with weekly self-directed modules (two to three hours per week) ...